Products

Recombinant Human PSMA Protein, His-tagged

Product Information
Catalog#:  MK1268H
Product Name:  Recombinant Human PSMA Protein, His-tagged
Description:  Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.
Source:  CHO 3E7 cells
Species:  Human
Tag:  His
Formulation:  Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Protein length:  Lys44-Ala750
Purity:  > 85% as determined by SDS-PAGE.
Storage:  Store under sterile conditions at -20 °C to -80 °C. Avoid repeated freeze-thaw cycles.
Reconstitution:  It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O or PBS up to 100 μg/mL.
Molecular Mass:  90-120 kDa
Stability:  Upon receiving, this product remains stable for 6 months at lower than -70 °C. Upon reconstitution, the product should be stable for 1 week at 4 °C or for 3 months at -20 °C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added.
Endotoxin:  < 1 EU/μg of protein by gel clotting method.
Notes:  Research Use Only. Not for use in clinical procedures.
Menu
Contact Us
Subscribe

Enter your email here to subscribe